Articles

Schaeffer fellow Matthew Fiedler submitted a comment letter to Centers the for Medicare and Medicaid Services on proposed rule changes to the Medicare Shared Savings Program. Some proposals may result in cost-savings and greater efficiencies, Fiedler recommends additional analysis in a number of areas.

Despite the overall success of the generic drug market, sudden price hikes are becoming more common according to new Schaeffer Center study

Sood served as the expert health economist for the Committee on Improving the Quality of Health Care Globally.

The Schaeffer Initiative researchers discuss bipartisan draft legislation that some say marks an important step forward in putting an end to surprise medical bills nationwide.

In The New England Journal of Medicine, Paul Ginsburg discusses the next phase of value-based payment systems and how healthcare payers and purchasers can ensure providers’ past investments become permanent reforms to the payment and care delivery process.

Dana Goldman and Anupam Jena write in The Washington Post that the Trump administration may succeed in lowering drug prices by fostering competition and innovation, and possibly ending kickbacks in the supply chain.

Dana Goldman and his colleagues have shown that such subscription models can improve outcomes and save money at the same time.

Pharmacy-benefit managers find ways to boost their bottom line at the expense of employers and patients, writes Geoffrey Joyce in Market Watch.

The authors argue that site-neutral payment under the CMS proposed rule should ultimately be applied to a much broader set of clinical services.

Our year-long study found that doctors prescribed fewer opioids after receiving letters telling them their patient had died from an opioid overdose.